← Back to Search

Monoclonal Antibodies

relatlimab for Cancer

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 2 years
Awards & highlights

Study Summary

This trial will study how well two drugs work together to treat advanced tumors, and how safe the combination is.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events (AEs)
Incidence of Adverse Events leading to discontinuation
Incidence of Serious Adverse Events (SAEs)
+6 more
Secondary outcome measures
Incidence of Adverese Events (AEs) in the broad SMQ of Anaphylactic Reaction
Incidence of anti-nivolumab antibodies and neutralizing antibodies (if applicable)
Incidence of anti-relatlimab antibodies and neutralizing antibodies (if applicable)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: nivolumab + relatlimab + rHuPH20Experimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Relatlimab
FDA approved
Hyaluronidase (human recombinant)
FDA approved
Nivolumab
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,634 Previous Clinical Trials
4,126,831 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
2019. "A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04112498.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top